• Login
  • Register
Nairametrics
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Economy
    • Nairalytics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Business News
    • Budget
    • Public Debt
    • Funds Management
    • Tax
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
    • Research Analysis
  • Recapitalization
    • Access Holdings Offer
    • Fidelity Bank Offer
    • GTCO Offer
    • Zenith Bank Offer
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Economy
    • Nairalytics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Business News
    • Budget
    • Public Debt
    • Funds Management
    • Tax
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
    • Research Analysis
  • Recapitalization
    • Access Holdings Offer
    • Fidelity Bank Offer
    • GTCO Offer
    • Zenith Bank Offer
Nairametrics
No Result
View All Result
Home Economy Socio Economic

China publicly presents its COVID-19 vaccines, 2 doses to cost below $146

Chike Olisah by Chike Olisah
September 7, 2020
in Socio Economic
Covid-19: AstraZeneca vaccine gets huge boost, produces immune response in elderly, Vaccine, COVID-19: Russia to roll out vaccine in September ahead of the West 

Covid-19: AstraZeneca vaccine

Share on FacebookShare on TwitterShare on Linkedin

China has publicly presented its homegrown covid-19 vaccines for the first time, as the country where the virus was first discovered, looks to shape the narrative surrounding the pandemic.

A lot of high hopes hang on the vaccine candidates produced by Chinese companies, Sinovac Biotech and Sinopharm which are on display at a Beijing trade fair this week.

Although none of these vaccine candidates has hit the market, the drugmakers hope that they will be approved after all-important phase 3 trials as early as the end of 2020.

RelatedStories

New COVID-19 Variant XEC not in Nigeria – FG 

New COVID-19 Variant XEC not in Nigeria – FG 

December 7, 2024
PDP calls for investigation into alleged fraud in Kebbi’s NG-Cares disbursement

PDP calls for investigation into alleged fraud in Kebbi’s NG-Cares disbursement

September 10, 2024

READ: TikTok in talks to move global headquarters to London over Chinese tussle with US

A Sinovac representative revealed that his company has already completed the construction of a vaccine factory which will be able to produce 300 million doses of the vaccine annually. This is just as people at the trade fair on Monday, crowded around booths showing the potential game-changing vaccines.

The Chinese state media and officials are making attempts to show the progress on domestic vaccines as a sign of Chinese leadership and resilience in the face of an unprecedented health threat that has pummeled the global economy.

READ: EU to buy $478 million WHO COVID-19 vaccine for low and middle income countries

The Chinese President, Xi Jinping, in May, pledged to make any potential vaccine developed by China, a global public good.

These potential Chinese vaccines on display, are among the about 10 vaccine candidates globally, to enter the final phase of the trials ahead of regulatory approval.

Sinopharm said that it expects the antibodies from its jab to last between 1 and 3 years, although the final result will only be made available after the trials.

READ: Covid-19: US to start manufacturing vaccine for the virus in next 4 weeks 

A Chinese media outfit had last month reported that the price of the vaccines will not be high. The report quoted the Sinopharm’s Chairman as saying that every 2 doses of its vaccine should cost below $146, while also telling the media that he has already been injected with one of the candidate vaccines.

China’s official Xinhua news agency reported Monday that another vaccine candidate which is being developed by Chinese military scientists can deal with mutations in the coronavirus.

READ: FAAN in recruitment scandal as politicians hijack process

As of last month, about 5.7 billion doses of the vaccines under development around the world had been pre-ordered.

However, the World Health Organization has warned that widespread immunization against Covid-19 may not be on the cards until the middle of next year.


Follow us for Breaking News and Market Intelligence.
Tags: Covid-19COVID-19 vaccinesSinopharmSinovac Biotech
Chike Olisah

Chike Olisah

Chike was a banker with over 11 years experience in retail and commercial banking, risk management, treasury portfolio management and relationship management. He also acquired some experience in financial management and do have some special interest in investment analysis and personal finance. He had stints with financial institutions like the former Intercontinental Bank and Fidelity Bank.

Related Posts

New COVID-19 Variant XEC not in Nigeria – FG 
Health

New COVID-19 Variant XEC not in Nigeria – FG 

December 7, 2024
PDP calls for investigation into alleged fraud in Kebbi’s NG-Cares disbursement
Business News

PDP calls for investigation into alleged fraud in Kebbi’s NG-Cares disbursement

September 10, 2024
Oyo state government
Business News

FG never gave N570 billion to 36 States – Seyi Makinde counters President Tinubu  

August 9, 2024
President Bola Tinubu,
Economy

FG asks World Bank to cancel $41.62 million balance of COVID-19 loan 

July 4, 2024
COVID-19, currency redesign, fuel subsidy removal are key drivers of food inflation in Nigeria – Ibrahim Maigari 
Economy

COVID-19, currency redesign, fuel subsidy removal are key drivers of food inflation in Nigeria – Ibrahim Maigari 

June 23, 2024
SERAP
Legal & Regulations

CBN vs SERAP: Court rules NGOs “cannot call itself pressure group”

May 28, 2024
Next Post
Why we experienced profit declines- Guinness Nigeria

Guinness gains on NSE despite N17 billion pre-tax loss

Comments 1

  1. Realist says:
    September 9, 2020 at 1:06 pm

    More suspicious of China as both the disease and visine are from the same lab. Time will tell.

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Emple
first bank
Zenth Bank









DUNS

Recent News

  • Cordros raises Lafarge’s 2025 target price to N104.71 after strong Q1 results
  • System Glitch: Court orders final forfeiture of N1.2bn stolen by individuals from Nigerian bank 
  • UK moves to tighten visa rules, targets legal migration surge 

Follow us on social media:

Recent News

Lafarge Africa posts N152.2 billion pre-tax profit in 2024, declares a final dividend of 120 kobo  

Cordros raises Lafarge’s 2025 target price to N104.71 after strong Q1 results

May 11, 2025
FCT High Court, Benjamin Joseph, zinox

System Glitch: Court orders final forfeiture of N1.2bn stolen by individuals from Nigerian bank 

May 11, 2025
  • iOS App
  • Android App
  • Contact Us
  • Home
  • Markets
  • Sectors
  • Economy
  • Business News
  • Financial Literacy
  • Disclaimer
  • Ads Disclaimer
  • Copyright Infringement

© 2025 Nairametrics

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Social Media Auto Publish Powered By : XYZScripts.com
No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Economy
    • Nairalytics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Business News
    • Budget
    • Public Debt
    • Funds Management
    • Tax
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
    • Research Analysis
  • Recapitalization
    • Access Holdings Offer
    • Fidelity Bank Offer
    • GTCO Offer
    • Zenith Bank Offer
  • Login
  • Sign Up

© 2025 Nairametrics